Clearside Biomedical, Inc. (CLSDQ): Nasdaq/NYSE listing notice — Clearside Biomedical receives Nasdaq delisting notice for bid price below $1.00

Clearside Biomedical, Inc.

Received Nasdaq notice on Sept 27, 2023 for non-compliance with minimum bid price rule.
Must regain compliance by March 25, 2024; bid price must close at $1.00+ for 10 consecutive days.
May transfer to Nasdaq Capital Market or effect a reverse stock split to cure the deficiency.
Failure to regain compliance could lead to delisting, impairing liquidity and capital access.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Clearside Biomedical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

September 27, 2023, Clearside Biomedical, Inc. (the “ Company ”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until March 25, 2024, to regain complia

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Clearside Biomedical, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-050819

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.